Orange Book product · Generic (ANDA)
LACOSAMIDE
LACOSAMIDE
At a glance
May 21, 2026
Approved
Generic (ANDA)
Application
AA
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 21, 2026
29 d ago
Today
Pharmaceutical detail
Active ingredient
LACOSAMIDE
Strength
10MG/ML
Dosage form
SOLUTION
Route
ORAL
TE code
AA
Application
ANDA 220366
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LACOSAMIDE
- 2023MOTPOLY XRBrand (NDA)
NDA 216185 · AUCTA
- 2010VIMPATBrand (NDA)
NDA 022255 · UCB INC
- 2008VIMPATBrand (NDA)
NDA 022254 · UCB INC
- 2008VIMPATBrand (NDA)
NDA 022253 · UCB INC
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220386 · REGCON HOLDINGS
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220268 · GLENMARK PHARMS
- 2025LACOSAMIDEGeneric (ANDA)
ANDA 219699 · AJENAT PHARMS
- 2025LACOSAMIDEGeneric (ANDA)
ANDA 218706 · WESTMINSTER PHARMS
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 218464 · ACELLA
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 214960 · SOMERSET THERAPS LLC
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 213109 · UNICHEM
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 208466 · MACLEODS PHARMS LTD
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
